LRRK2
Coverage of LRRK2 in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about a Parkinson’s drug setback, a Merck lung cancer therapy, and more
Biogen and Denali Therapeutics' experimental Parkinson's drug targeting the LRRK2 protein failed to slow disease progression in a clinical trial, dealing a setback to a promising scientific approach. Separately, Genentech is offering researchers up to $125,000 in grants to produce papers on pharmaceutical pricing policies and innovation, raising questions about the independence of such research.
- STAT+: Closely watched experimental Parkinson’s drug fails key clinical trial
Biogen and Denali Therapeutics announced that their experimental Parkinson's disease drug failed to meet primary endpoints in a Phase 2b clinical trial involving 648 patients. The drug targeted LRRK2 protein, which researchers had hoped could benefit all Parkinson's patients, but the results represent a significant setback to this therapeutic approach.